J. Cottalorda

发表

Evaluation of the Genotypic Prediction of HIV-1 Coreceptor Use versus a Phenotypic Assay and Correlation with the Virological Response to Maraviroc: the ANRS GenoTropism Study

C. Charpentier, B. Masquelier, J. Izopet, 2010, Antimicrobial Agents and Chemotherapy.

Do viral load and CD8 cell count at initiation of tritherapy influence the increase of CD4 T‐cell count?

C. Pradier, P. Dellamonica, P. Roger, 1998, AIDS.

Direct-acting antiviral treatment in adults infected with hepatitis C virus: Reactivation of hepatitis B virus coinfection as a further challenge.

R. Anty, J. Courjon, V. Giordanengo, 2016, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Erratum to ‘HMGB1/anti-HMGB1 antibodies define a molecular signature of early stages of HIV-Associated Neurocognitive Disorders (HAND)’

S. Chanalet, M. Ticchioni, C. Pradier, 2017, Heliyon.

HMGB1/anti-HMGB1 antibodies define a molecular signature of early stages of HIV-Associated Neurocognitive Disorders (HAND)

S. Chanalet, M. Ticchioni, C. Pradier, 2017, Heliyon.

Autoantibodies directed against CD43 molecules with an altered glycosylation status on human immunodeficiency virus type 1 (HIV-1)-infected CEM cells are found in all HIV-1+ individuals.

A. Doglio, V. Giordanengo, J. Lefebvre, 1995, Blood.

Bridging the gap between adult and paediatric outcomes in HIV-1 vertically infected children: a single-centre comparison with adult data

F. Berthier, F. Monpoux, C. Pradier, 2009, Acta paediatrica.

National survey of the prevalence and conditions of selection of HIV‐1 reverse transcriptase K70E mutation

V. Calvez, C. Delaugerre, S. Yerly, 2008, Journal of medical virology.

Genotypic and Phenotypic Resistance Patterns of Human Immunodeficiency Virus Type 1 Variants with Insertions or Deletions in the Reverse Transcriptase (RT): Multicenter Study of Patients Treated with RT Inhibitors

V. Calvez, F. Brun-Vézinet, B. Masquelier, 2001, Antimicrobial Agents and Chemotherapy.

Stavudine, lamivudine and indinavir in children with advanced HIV-1 infection: preliminary experience.

F. Monpoux, N. Sirvent, J. Cottalorda, 1997, AIDS.

Neonatal characteristics in rapidly progressive perinatally acquired HIV-1 disease

B. Masquelier, H. Fleury, C. Rouzioux, 1996 .

Selection of the R263K mutation to dolutegravir in cerebrospinal fluid HIV-1 virus in one patient with HIV-associated neurocognitive disorders.

B. Dunais, J. Cottalorda, J. Durant, 2016, AIDS.

Effect of indinavir and higher CD4+ T-cell count on viral load response after 6 months of highly active antiretroviral therapy.

A. Pesce, P. Carrieri, C. Pradier, 1999, Clinical therapeutics.

National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001-2011.

V. Calvez, C. Charpentier, F. Brun-Vézinet, 2013, The Journal of antimicrobial chemotherapy.

French National Sentinel Survey of Antiretroviral Drug Resistance in Patients With HIV-1 Primary Infection and in Antiretroviral-Naive Chronically Infected Patients in 2001-2002

F. Brun-Vézinet, P. André, B. Masquelier, 2005, Journal of acquired immune deficiency syndromes.

HIV-1 and persistent clinical latency, TAR element analysis and improved method for in vitro viral reactivation.

P. Dellamonica, J. Lesimple, D. March, 2007, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Levels of intracellular HIV-DNA in patients with suppressive antiretroviral therapy

C. Charpentier, L. Cuzin, M. Guiguet, 2015, AIDS.

Partial splenectomy in a child with human immunodeficiency virus-related immune thrombocytopenia.

F. Monpoux, J. Cottalorda, J. Kurzenne, 1999, Journal of pediatric hematology/oncology.

Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France.

V. Calvez, C. Charpentier, F. Brun-Vézinet, 2010, The Journal of antimicrobial chemotherapy.

Neonatal characteristics in rapidly progressive perinatally acquired HIV-1 disease. The French Pediatric HIV Infection Study Group.

B. Masquelier, C. Rouzioux, D. Dormont, 1996, JAMA.

Zidovudine genotypic resistance in HIV-1-infected newborns in the French perinatal cohort.

B. Masquelier, H. Fleury, C. Rouzioux, 2001 .

Virological and Pharmacological Parameters Predicting the Response to Lopinavir-Ritonavir in Heavily Protease Inhibitor-Experienced Patients

V. Calvez, D. Kempf, M. King, 2005, Antimicrobial Agents and Chemotherapy.

Relevance of lipopolysaccharide levels in HIV-associated neurocognitive impairment: the Neuradapt study

M. Ticchioni, Jacques Durant, C. Pradier, 2013, Journal of NeuroVirology.

Persistent viral load in patients on HAART is associated with a higher level of activation-induced apoptosis of CD4(+) T cells.

M. Ticchioni, A. Bernard, P. Dellamonica, 2001, The Journal of antimicrobial chemotherapy.

Prevalence of resistance mutations in antiretroviral-naive chronically HIV-infected patients in 1998: a French nationwide study

V. Calvez, B. Masquelier, D. Costagliola, 2001, AIDS.

Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort

C. Charpentier, C. Katlama, Y. Yazdanpanah, 2018, The Journal of antimicrobial chemotherapy.

An undetectable polymerase chain reaction signal in routine HIV plasma viral load monitoring is associated with better virological outcomes in patients receiving highly active antiretroviral therapy

C. Delaugerre, C. Delpierre, L. Cuzin, 2013, HIV medicine.

A decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replication

M. Ticchioni, Jacques Durant, C. Pradier, 2016, Journal of NeuroVirology.

The role of lipopolysaccharide as a marker of immune activation in HIV-1 infected patients: a systematic literature review

M. Ticchioni, P. Mercié, P. Dellamonica, 2012, Virology Journal.

Can high central nervous system penetrating antiretroviral regimens protect against the onset of HIV-associated neurocognitive disorders?

M. Ticchioni, C. Pradier, V. Biscay, 2014, AIDS.

The role of lipopolysaccharide as a marker of immune activation in HIV-1 infected patients: a systematic literature review

M. Ticchioni, P. Mercié, P. Dellamonica, 2012, Virology Journal.

Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen

V. Calvez, C. Charpentier, F. Brun-Vézinet, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Relevance of lipopolysaccharide levels in HIV-associated neurocognitive impairment: the Neuradapt study

M. Ticchioni, C. Pradier, C. Lebrun-Frénay, 2013, Journal of NeuroVirology.

Heparine-like anticoagulant vasculitis associated with severe primary infection by HIV.

J. Michiels, P. Dellamonica, J. Bayle, 1990, AIDS.

Virologically suppressed patients with asymptomatic and symptomatic HIV‐associated neurocognitive disorders do not display the same pattern of immune activation

M. Ticchioni, Jacques Durant, C. Pradier, 2015, HIV medicine.

Factors Associated with Virological Response to Etravirine in Nonnucleoside Reverse Transcriptase Inhibitor-Experienced HIV-1-Infected Patients

V. Calvez, C. Charpentier, C. Delaugerre, 2009, Antimicrobial Agents and Chemotherapy.

Prevalence of complete resistance to at least two classes of antiretroviral drugs in treated HIV‐1‐infected patients: A French nationwide study

V. Calvez, F. Brun-Vézinet, B. Masquelier, 2005, Journal of medical virology.

Prevalence of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance-associated mutations and polymorphisms in NNRTI-naïve HIV-infected patients

F. Clavel, P. Clevenbergh, J. Schmit, 2002, HIV clinical trials.